Sahajanand Medical Technologies
LIVEIPO Date: 15 Oct - 19 Oct 2026
Listing Date: 23 Oct 2026
Price Range
₹327 to ₹344
Issue Size
475 Cr
Min Investment
₹14,061
Min Application
43 Shares
Schedule of Sahajanand Medical Technologies
Issue open date
15 Oct 2026
Issue close date
19 Oct 2026
UPI mandate deadline
19 Oct 2026 (5 PM)
Allotment finalization
21 Oct 2026
Share credit
22 Oct 2026
Listing date
23 Oct 2026
Mandate end date
3 Nov 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 475 Cr |
| Fresh Issue | 0 Cr |
| Offer for Sale | 1.38 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 21 Oct 2026 |
| Allotment Link | {Link} |
Grey Market Premium
NewGrey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | IPO Price | GMP | Est. Listing Price |
|---|---|---|---|
| 16 Oct 2026Latest | ₹344 | ₹38 | ₹382(+11.05%) |
| 15 Oct 2026 | ₹344 | ₹46 | ₹390(+13.37%) |
| 14 Oct 2026 | ₹344 | ₹41 | ₹385(+11.92%) |
| 13 Oct 2026 | ₹344 | ₹35 | ₹379(+10.17%) |
| 12 Oct 2026 | ₹344 | ₹35 | ₹379(+10.17%) |
| 11 Oct 2026 | ₹344 | ₹0 | ₹344(0%) |
Performance Sahajanand Medical Technologies
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| ₹327 to ₹344 | .... | .... | .... |
About Sahajanand Medical Technologies
Sahajanand Medical Technologies Limited is an Indian medical-device manufacturer that develops, manufactures and markets cardiovascular products for the treatment of heart and vascular diseases. Its business primarily operates through two segments: Vascular Intervention devices, including coronary stents and balloon catheters, and Structural Heart devices, including transcatheter aortic valves and occluders. Its flagship product, Supraflex Cruz, is a biodegradable polymer-based drug-eluting coronary stent and a major contributor to revenue. The company operates manufacturing facilities in Surat, Hyderabad and Thailand, supported by research and development capabilities and an international distribution network serving India, Europe and other global markets.
| Founded in | 2001 |
| Managing director | Bhargav Dhirajlal Kotadia |
| Parent organization |
Financial Overview
Strengths
4- 1
Established cardiovascular product portfolio. The company offers coronary stents, balloon catheters, transcatheter aortic valves and occluders, serving multiple areas of cardiovascular treatment.
- 2
International market presence. Its distribution network and subsidiaries support sales across India, Europe and other international markets, reducing dependence on a single geographical market.
- 3
Manufacturing and R&D capabilities. Facilities in Surat, Hyderabad and Thailand support product manufacturing, while continued research and development investment helps the company improve existing products and develop new medical technologies.
- 4
Recognised flagship product. Supraflex Cruz is an established drug-eluting stent in the company's portfolio. It contributed approximately 37.17% of revenue from operations in FY2026, demonstrating its commercial importance.
Risks
4- 1
Dependence on Supraflex Cruz. The flagship stent contributed approximately 37.17% of FY2026 revenue. Reduced demand, stronger competition or product-related regulatory issues could materially affect sales and profitability.
- 2
Strict regulatory requirements. Cardiovascular devices require regulatory approvals, certifications and ongoing compliance across different countries. Delays or failure to maintain approvals could restrict product sales in important markets.
- 3
Dependence on suppliers. The company's top 10 suppliers accounted for approximately 58.88% of purchases in FY2026, exposing it to supply disruptions, higher raw-material costs and potential dependence on individual suppliers.
- 4
High research and development expenditure. The company invests substantially in developing and improving medical devices. If new products fail to obtain regulatory approval or achieve commercial acceptance, the associated R&D expenditure may not generate expected returns.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 0.37 |
| Non-Institutional Investors (NIIs) | 0.2 |
| Retail Individual Investors (RIIs) | 0.41 |
| Employee | 0.08 |
| Total | 0.35 |